Tempus AI recovers 15% as Wall Street downplays Spruce Point allegations

Tempus AI (TEM) shares rebounded 15% after a prior week's 13% decline triggered by a Spruce Point Capital short-seller report alleging misrepresentation of AI revenue and questionable related-party transactions; TD Cowen countered, calling the selloff overdone and reiterating a Buy rating with a $62 price target, stating many concerns were previously known or exaggerated. Despite the short report's claims of potential downside risk and scrutiny of CEO Eric Lefkofsky's history, investors appear to have dismissed the allegations, with the average sell-side price target remaining at $66.82.

Analysis

Tempus AI (TEM) shares experienced a significant 15% rebound, partially offsetting a 13% weekly loss incurred following a critical short-seller report from Spruce Point Capital. The report alleged Tempus AI misrepresented the significance of its artificial intelligence operations, citing that AI-related revenue constituted only $12.4 million in 2024, less than 2% of total revenue, thereby creating a 'disconnect between the company’s branding and its financial reality.' Spruce Point also raised concerns about related-party revenue, specifically a $200 million customer contract with Pathos AI and a $95 million joint venture with SoftBank (TYO:9984), questioned CEO Eric Lefkofsky's leadership history referencing past corporate failures, and highlighted aggressive billing practices, including the use of reimbursement code 81479, potentially inflating revenue. The short-seller warned of a potential 50% to 60% downside risk. Conversely, TD Cowen analyst Dan Brennan characterized the selloff as 'largely overdone,' reiterating a Buy rating and a $62 price target. Brennan acknowledged that while some new issues raised by Spruce Point were 'worth exploring' and investor concerns about related-party transactions were valid, many points were 'already known' or 'exaggerated,' and some assertions were 'misleading and/or incorrect.' TD Cowen noted the stock's near 100% year-to-date appreciation prior to the report made it susceptible to negative catalysts. Despite the allegations, investor sentiment appears to have shifted, with the market 'buying the dip,' and the average sell-side price target remains robust at $66.82, indicating continued broader analyst support for the precision medicine firm amidst this volatility.

Key Decisions for Investors

• Investors should carefully evaluate the conflicting narratives surrounding Tempus AI, weighing the serious allegations from Spruce Point Capital regarding AI revenue contribution, related-party transactions, and governance against TD Cowen's rebuttal and the broader positive Wall Street consensus.
• Monitor closely for any official company responses or further disclosures addressing the specific claims, particularly concerning the materiality of AI in its business model and the nature of its significant customer contracts.
• Given the stock's sharp rebound and substantial prior gains, consider the heightened volatility and assess whether the current valuation adequately reflects both the growth prospects championed by analysts and the risks highlighted by the short-seller report before making new investment decisions or adjusting existing positions.